Approval · Notice of Compliance 37151 · 2026
OJJAARA: Notice of Compliance 37151
Issued March 20, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37151
- Date
- March 20, 2026
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OJJAARA | Not yet assigned | — |
Medicinal ingredients
- MOMELOTINIB DIHYDROCHLORIDE 100 MG per TAB
- MOMELOTINIB DIHYDROCHLORIDE 150 MG per TAB
- MOMELOTINIB DIHYDROCHLORIDE 200 MG per TAB